These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 34632682)

  • 21. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
    Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
    Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
    Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M
    AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing antiretroviral therapy for children living with HIV: Experience from an observational cohort in Lesotho.
    Tukei VJ; Herrera N; Masitha M; Masenyetse L; Mokone M; Mokone M; Maile L; Gill MM
    PLoS One; 2023; 18(7):e0288619. PubMed ID: 37459349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-Year Outcomes of Treatment-Experienced Adults After Programmatic Transitioning to Dolutegravir: Longitudinal Data From the VICONEL Human Immunodeficiency Virus Cohort in Lesotho.
    Tschumi N; Lerotholi M; Motaboli L; Mokete M; Labhardt ND; Brown JA
    Clin Infect Dis; 2023 Nov; 77(9):1318-1321. PubMed ID: 37358226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy.
    Lahiri CD; Brown NL; Ryan KJ; Acosta EP; Sheth AN; Mehta CC; Ingersoll J; Ofotokun I
    AIDS; 2018 Sep; 32(15):2151-2159. PubMed ID: 30005011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
    Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
    Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viral load non-suppression status among women exposed to Dolutegravir-based versus Efavirenz-based regimens in Ethiopia: A before-and-after study.
    Facha W; Tadesse T; Wolka E; Astatkie A
    PLoS One; 2024; 19(6):e0305331. PubMed ID: 38857273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho.
    Amstutz A; Nsakala BL; Vanobberghen F; Muhairwe J; Glass TR; Namane T; Mpholo T; Battegay M; Klimkait T; Labhardt ND
    PLoS Med; 2020 Sep; 17(9):e1003325. PubMed ID: 32936795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort.
    Chan P; Goh O; Kroon E; Colby D; Sacdalan C; Pinyakorn S; Prueksakaew P; Reiss P; Ananworanich J; Valcour V; Spudich S; Paul R;
    AIDS Res Ther; 2020 Jan; 17(1):1. PubMed ID: 31907064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
    Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
    BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.
    Mondi A; Cozzi-Lepri A; Tavelli A; Rusconi S; Vichi F; Ceccherini-Silberstein F; Calcagno A; De Luca A; Maggiolo F; Marchetti G; Antinori A; d'Arminio Monforte A;
    J Int AIDS Soc; 2019 Jan; 22(1):e25227. PubMed ID: 30663278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
    Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
    Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics.
    Fokam J; Nka AD; Mamgue Dzukam FY; Efakika Gabisa J; Bouba Y; Tommo Tchouaket MC; Ka'e AC; Ngoufack Jagni Semengue E; Takou D; Moudourou S; Fainguem N; Pabo W; Nayang Mundo RA; Kengni Ngueko AM; Ambe Chenwi C; Flore Yimga J; Nnomo Zam MK; Simo Kamgaing R; Tangimpundu C; Kamgaing N; Njom-Nlend AE; Ndombo Koki P; Kesseng D; Ndiang Tetang S; Kembou E; Ebiama Lifanda L; Pamen B; Ketchaji A; Saounde Temgoua E; Billong SC; Zoung-Kanyi Bissek AC; Hadja H; Halle EG; Colizzi V; Perno CF; Sosso SM; Ndjolo A
    Medicine (Baltimore); 2023 May; 102(20):e33737. PubMed ID: 37335723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital.
    Todd S; Rafferty P; Walker E; Hunter M; Dinsmore WW; Donnelly CM; McCarty EJ; Quah SP; Emerson CR
    Int J STD AIDS; 2017 Oct; 28(11):1074-1081. PubMed ID: 28118801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study.
    Buju RT; Akilimali PZ; Kamangu EN; Mesia GK; Kayembe JMN; Situakibanza HN
    Int J Environ Res Public Health; 2022 Jan; 19(3):. PubMed ID: 35162109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
    Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
    Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.
    Dooley KE; Kaplan R; Mwelase N; Grinsztejn B; Ticona E; Lacerda M; Sued O; Belonosova E; Ait-Khaled M; Angelis K; Brown D; Singh R; Talarico CL; Tenorio AR; Keegan MR; Aboud M;
    Clin Infect Dis; 2020 Feb; 70(4):549-556. PubMed ID: 30918967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Barriers to viral load suppression among adolescents living with HIV on anti-retroviral therapy: a retrospective study in Tanga, Tanzania.
    Mushy SE; Mtisi E; Mkawe S; Mboggo E; Ndega J; Yahya-Malima KI; Kamugunya D; Kilimba ES; Mlay BS; Muya A; Ngalesoni F
    AIDS Res Ther; 2024 May; 21(1):35. PubMed ID: 38778318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda.
    Nakatudde I; Katana E; Agnes Odongpiny EL; Nalugga EA; Castelnuovo B; Fowler MG; Musoke P
    AIDS Res Ther; 2024 Apr; 21(1):23. PubMed ID: 38637785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unlocking the potential: exploring the impact of dolutegravir treatment on body mass index improvement in underweight adults with HIV in Malawi.
    Maphosa T; Dunga S; Makonokaya L; Woelk G; Maida A; Wang A; Ahimbisibwe A; Chamanga RK; Zimba SB; Kayira D; Machekano R
    BMC Public Health; 2024 May; 24(1):1321. PubMed ID: 38755632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.